✕
Journal of Obesity & Metabolic Syndrome

Search

Articles

Medication >

view0 view388 down101

Short Communication 2024-09-30

Effect of Whole-Body Electrical Muscle Stimulation Training on Inflammatory and Anti-inflammatory Cytokines in Overweight Men

Mohammad Reza Pour Salehi, Jalil Reisi , Sayed Mohammad Marandi, Milad Abdollahi
J Obes Metab Syndr 2024; 33(3): 270-274
https://doi.org/10.7570/jomes23070
Full Text PDF PMC
view0 view555 down205

Original Article 2024-09-30

Combination of Metformin and Epigallocatechin-3-Gallate Lowers Cortisol, 11β-Hydroxysteroid Dehydrogenase Type 1, and Blood Glucose Levels in Sprague Dawley Rats with Obesity and Diabetes

Diana Mazaya Atsarina, Nyoman Suci Widyastiti, Muflihatul Muniroh, Neni Susilaningsih, Nani Maharani
J Obes Metab Syndr 2024; 33(3): 261-269
https://doi.org/10.7570/jomes23080
Full Text PDF PMC
view2 view924 down452

Original Article 2024-03-30

Obesity as a Limiting Factor for Remote Ischemic Postconditioning-Mediated Neuroprotection after Stroke

Klaudia Kotorová, Jana Končeková, Miroslav Gottlieb, Martin Bona, Petra Bonová
J Obes Metab Syndr 2024; 33(1): 76-87
https://doi.org/10.7570/jomes23038
Full Text PDF PMC
view1 view1144 down397

Editorial 2023-12-30

The Transformative Impact of New Anti-Obesity Medications: A Paradigm Shift in Medical Practice?

Arya M. Sharma
J Obes Metab Syndr 2023; 32(4): 285-288
https://doi.org/10.7570/jomes23078
Full Text PDF PMC
view13 view6075 down2424

Review 2023-06-30

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon

Eonju Jeon, Ki Young Lee , Kyoung-Kon Kim
J Obes Metab Syndr 2023; 32(2): 106-120
https://doi.org/10.7570/jomes23032
Full Text PDF PMC
view0 view951 down422

Editorial 2023-06-30

The Prevalence of Abdominal Obesity and Metabolic Syndrome in Korean Children and Adolescents

Ja Hyang Cho
J Obes Metab Syndr 2023; 32(2): 103-105
https://doi.org/10.7570/jomes23025
Full Text PDF PMC
view37 view11449 down4026

Review 2023-03-30

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

Rachel Sinha, Dimitris Papamargaritis , Jack A. Sargeant, Melanie J. Davies
J Obes Metab Syndr 2023; 32(1): 25-45
https://doi.org/10.7570/jomes22067
Full Text PDF PMC
view5 view2527 down535

Original Article 2022-09-30

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting

Hae-Jin Ko, Jin-Wook Kim, Soo Lim
J Obes Metab Syndr 2022; 31(3): 254-262
https://doi.org/10.7570/jomes22029
Full Text PDF PMC
view17 view9640 down3153

Review 2022-03-30

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?

Han Na Jung, Chang Hee Jung
J Obes Metab Syndr 2022; 31(1): 28-36
https://doi.org/10.7570/jomes22012
Full Text PDF PMC
view11 view5473 down939

Original Article 2021-12-30

Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis

Yun Kyung Cho, Ye-Jee Kim, Chang Hee Jung
J Obes Metab Syndr 2021; 30(4): 336-344
https://doi.org/10.7570/jomes21061
Full Text PDF PMC
view7 view2688 down755

Review 2021-09-30

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes

Jared Rosenberg, Jordan Jacob, Priya Desai, Jeremy Park, Lorin Donovan, Joon Young Kim
J Obes Metab Syndr 2021; 30(3): 233-247
https://doi.org/10.7570/jomes21053
Full Text PDF PMC
view9 view3199 down1103

Review 2021-09-30

Unravelling Polycystic Ovary Syndrome and Its Comorbidities

Kyung-Wook Kim
J Obes Metab Syndr 2021; 30(3): 209-221
https://doi.org/10.7570/jomes21043
Full Text PDF PMC
view37 view11256 down4399

Review 2021-09-30

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

Donna H. Ryan
J Obes Metab Syndr 2021; 30(3): 196-208
https://doi.org/10.7570/jomes21033
Full Text PDF PMC
view9 view4015 down1011

Review 2021-06-30

Oxytocin: A Potential Therapeutic for Obesity

Soo Min Hong, Jeong-Kyung Ko, Jung-Joon Moon, Youl-Ri Kim
J Obes Metab Syndr 2021; 30(2): 115-123
https://doi.org/10.7570/jomes20098
Full Text PDF PMC
view24 view4556 down1326

Review 2021-03-30

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes

Young-Gyun Seo
J Obes Metab Syndr 2021; 30(1): 12-19
https://doi.org/10.7570/jomes20059
Full Text PDF PMC
view23 view5932 down2136

Review 2021-03-30

Menthol to Induce Non-shivering Thermogenesis via TRPM8/PKA Signaling for Treatment of Obesity

Owen Davis Sanders , Jayalekshmi Archa Rajagopal, Lekshmy Rajagopal
J Obes Metab Syndr 2021; 30(1): 4-11
https://doi.org/10.7570/jomes20038
Full Text PDF PMC
view12 view3726 down1406

Original Article 2020-09-30

Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease

Ju-Young Hong, Keun-Young Park, Jong-Dai Kim, Won-Min Hwang, Dong-Mee Lim
J Obes Metab Syndr 2020; 29(3): 215-221
https://doi.org/10.7570/jomes20040
Full Text PDF PMC
view1 view2538 down742

Original Article 2020-06-30

Examination of Patients’ Regular Participation at an Obesity Center to Evaluate the Effects on Mental Status and Blood Parameters

Duygu İlke Yıldırım , Mehmet Ali Eryılmaz, Memduha Aydın
J Obes Metab Syndr 2020; 29(2): 150-157
https://doi.org/10.7570/jomes20030
Full Text PDF PMC
view17 view4623 down2549

Review 2020-06-30

Current Long-Term Pharmacotherapies for the Management of Obesity

Bo-Yeon Kim, Seon Mee Kang, Jee-Hyun Kang, Kyoung Kon Kim, Bomtaeck Kim, Seung Jun Kim, Yang-Hyun Kim, Jung-Hwan Kim, Jae Hyun Kim, Ga Eun Nam, Ji Yeon Park, Jang Won Son, Hye-Jung Shin, Tae Jung Oh, Hyug Lee, Eon-Ju Jeon, Sochung Chung, Yong Hee Hong, Chong Hwa Kim , Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)
J Obes Metab Syndr 2020; 29(2): 99-109
https://doi.org/10.7570/jomes20010
Full Text PDF PMC
view15 view3392 down1044

Original Article 2019-12-30

Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease

Sook Jung Lee, Kook Hyung Lee, Hyun Geong Oh, Hye Ji Seo, Soo Jin Jeong, Chong Hwa Kim
J Obes Metab Syndr 2019; 28(4): 254-261
https://doi.org/10.7570/jomes.2019.28.4.254
Full Text PDF PMC
view52 view5810 down2667

Review 2019-12-30

Effect of Diet on the Gut Microbiota Associated with Obesity

Bohkyung Kim, Ha-Neul Choi, Jung-Eun Yim
J Obes Metab Syndr 2019; 28(4): 216-224
https://doi.org/10.7570/jomes.2019.28.4.216
Full Text PDF PMC
view15 view4458 down1831

Review 2019-09-30

The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications

Tae Jung Oh
J Obes Metab Syndr 2019; 28(3): 158-166
https://doi.org/10.7570/jomes.2019.28.3.158
Full Text PDF PMC
view7 view3269 down1132

Original Article 2019-06-30

Zaluzanin C Inhibits Differentiation of 3T3-L1 Preadipocytes into Mature Adipocytes

Sang Hee Kwak, Yoon Hee Kim
J Obes Metab Syndr 2019; 28(2): 105-111
https://doi.org/10.7570/jomes.2019.28.2.105
Full Text PDF PMC
view15 view3434 down1335

Review 2019-03-30

The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Chan-Hee Jung, Ji-Oh Mok
J Obes Metab Syndr 2019; 28(1): 18-29
https://doi.org/10.7570/jomes.2019.28.1.18
Full Text PDF PMC

jomes

September, 2024
Vol.33 No.3

Current Issue
Archives

Mostly popular keywords